Frost & Sullivan Recognizes Oragenics for its Unique ProBiora3

Posted: October 24, 2011
Frost & Sullivan Recognizes Oragenics for its Unique ProBiora3® that Promotes Oral Health for Both Humans and Companion Animals
Oragenics’ Product Promotes Fresh Breath, Oral Hygiene and Tooth Whitening Naturally
For Media Consideration:
Tampa, FL (10/4/2011) – Florida-based nutraceutical company, Oragenics, Inc. (OTCQB: ORNI), announced today that it was honored by Frost & Sullivan, the leading global business research and consulting firm, with the 2011 North American Product Differentiation Excellence Award. Frost & Sullivan’s international research platform singled out Oragenics, Inc.’s oral care probiotic products for humans and companion pets.
The patented blend of probiotics in ProBiora3® makes this product the only one in the market to naturally aid fresh breath, oral hygiene, and tooth whitening. EvoraPlus® is a dissolvable mint taken once daily that whitens teeth and helps to support tooth and gum health while freshening breath. EvoraPet™ is a powder that is sprinkled onto pet food, which helps to naturally promote fresher breath and cleaner, whiter teeth. ProBiora3® is 100% natural and made in the U.S.A. in an FDA-registered and GMP-certified facility. Frost & Sullivan, in its 50th year in business, is a global research organization of 1,800 analysts and consultants who monitor more than 300 industries and 250,000 companies. “The manufacturing process for ProBiora3® is entrusted to partners that are good manufacturing practice-compliant and undergo a strict audit process by Oragenics,” says Frost & Sullivan Senior Research Analyst, Dr. Kaushik Shankar. “The company has in-house capabilities for testing the probiotic blend for viability, release kinetics, and long-term storage capabilities.”
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices in the industry. “Oragenics is deeply honored to be the recipient of such a prestigious award,” stated John Bonfiglio, PhD, Chief Executive Officer of Oragenics. “This recognition of Oragenics’ accomplishments in the oral care probiotics market is a direct result of the total commitment and focus of our scientific, marketing and senior management team.”

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.awards.frost.com.

About Oragenics, Inc.
Oragenics is a leading nutraceutical company focused on oral care probiotics for humans and companion pets. The Company's proprietary products Evora® and ProBiora3® are currently sold in over 20 countries. In addition, Oragenics has a robust pipeline of therapeutic products targeting infectious disease.
Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company’s current views with respect to future events and financial performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.
For more information about Probiora3, visit www.oragenics.com.
Views: 16
Sponsors
Sally Gross, Member Services Specialist
Phone: +1-480-445-9710
Email: sally@farranmedia.com
©2025 Hygienetown, a division of Farran Media • All Rights Reserved
9633 S. 48th Street Suite 200 • Phoenix, AZ 85044 • Phone:+1-480-598-0001 • Fax:+1-480-598-3450